Zapizolam
![]() | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.058.774 |
| Chemical and physical data | |
| Formula | C15H9Cl2N5 |
| Molar mass | 330.17 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Zapizolam[1] is a pyridodiazepine drug, which is a benzodiazepine analog of pyridotriazolodiazepine group. It has sedative and anxiolytic effects similar to those produced by benzodiazepine derivatives, and has been sold illicitly as a designer drug.[2]
References
- ^ DE Withdrawn 2649116, Von Bebenburg W, Schulmeyer N, Jakovlev V, "Neue 6-aryl-s-triazolo-(4,3-a)- pyrido-(2,3-f)-1,4-diazepine", published 18 May 1977, assigned to Evonik Operations GmbH
- ^ Zawilska JB, Wojcieszak J (July 2019). "An expanding world of new psychoactive substances-designer benzodiazepines". Neurotoxicology. 73: 8–16. doi:10.1016/j.neuro.2019.02.015. PMID 30802466. S2CID 73461430.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.
